Caraco launches generic Trileptal
DETROIT Caraco Pharmaceuticals has launched a generic version of Novartis’ Trileptal, on behalf of Sun Pharmaceuticals, who recently received approval from the Food and Drug Administration for the generic version.
The generic, oxcarbazepine, is used for monotherapy or adjunctive therapy for the treatment of partial seizures in adults as well as monotherapy and adjunctive therapy in children aged 4 years and older with epilepsy.
Trileptal had sales of about $640 million for the year ended June 30, 2007, according to IMS data. The generic will be available in three strengths, 150 mg, 300 mg and 600 mg.